Table 1 Comparison of recipient characteristics between the DGF and non-DGF groups in the development cohort
Recipient characteristics | Non-DGF Group | DGF Group | P value | |
|---|---|---|---|---|
|  | n = 396 | n = 96 |  | |
Age (years) | 36.08 ± 9.61 | 37.66 ± 8.57 | 0.142 | |
Male, n (%) | 275 (69.4%) | 72 (75.0%) | 0.319 | |
BMI (kg/m2) | 20.10 ± 1.18 | 19.98 ± 0.79 | 0.798 | |
Primary disease, n (%) | 0.895 | |||
Chronic glomerulonephritis | 283 (71.5%) | 75 (78.1%) | Â | |
IgA nephropathy | 56 (14.1%) | 10 (10.4%) | Â | |
Diabetic nephropathy | 10 (2.5%) | 2 (2.1%) | Â | |
Polycystic kidney | 18 (4.5%) | 4 (4.2%) | Â | |
Purpura nephritis | 9 (2.3%) | 4 (4.2%) | Â | |
Others | 20 (5.1%) | 1 (1.0%) | Â | |
Hemodialysis (before transplant), n (%) | 333 (84.1%) | 74 (77.9%) | 0.401 | |
Dialysis duration (months) | 19.71 ± 19.49 | 24.04 ± 26.80 | 0.075 | |
HLA mismatches | 2.0 (1.0, 2.0) | 2.0 (1.0, 2.0) | 0.337 | |
PRA positive, n (%) | 59 (14.8%) | 6 (6.3%) | 0.028 | |
Pre-transplant serum creatinine (µmol/L) | 892.41 ± 254.83 | 938.02 ± 244.74 | 0.114 | |
Induction therapy, n (%) | 0.581 | |||
r-ATG | 255 (64.6%) | 62 (64.6%) | Â | |
ATG-F | 57 (14.4%) | 18 (18.8%) | Â | |
Basiliximab | 58 (14.7%) | 10 (10.4%) | Â | |
Others | 26 (6.56%) | 6 (6.3%) | Â | |